Rezafungin for Salvage or Consolidation Therapy of Invasive Fungal Disease: Experience in Real‐World Clinical Practice
Mycoses · 2026-02 · 69 (2)
DOI: 10.1111/myc.70163 ↗Kurz gefasst
Fachartikel in der Zeitschrift Mycoses, online erschienen am 20.02.2026. Verfasst von Jorge Boán und 10 weiteren Autor:innen. Beteiligte Einrichtung: Unit of Infectious Diseases, Hospital Universitario 12 de Octubre, Instituto de Investigación Hospital 12 de Octubre (imas12), Madrid, Spain. Hauptthemen laut MEDLINE: Antifungal Agents, Echinocandins, Salvage Therapy, Invasive Fungal Infections. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 47 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Instituto de Salud Carlos III (ISCIII), Spanish Ministry of Science, Innovation and Universities., Instituto de Salud Carlos III.
Abstract (Originalsprache)
Background
Echinocandins are the first‐line treatment for invasive candidiasis. Rezafungin is a novel echinocandin with improved pharmacokinetic properties that allow for once‐weekly intravenous administration, offering potential advantages in complex clinical settings.
Objectives
We aimed to describe our real‐world experience with rezafungin for the treatment of invasive fungal disease (IFD). Patients A retrospective analysis of consecutive patients treated with rezafungin for proven IFD at our center between September 2022 and December 2025 was conducted.
Results
We included 13 patients (mean age: 59.4 ± 17.8 years). Main predisposing conditions included immunosuppression (53.8% [solid organ transplantation in 30.8%]), solid cancer (30.8%) and recent surgical intervention (38.5%). Most frequent Candida species were C. albicans (38.5%), C. parapsilosis (30.8%) and Nakaseomyces glabratus (15.4%). One patient had necrotizing gingival infection due to Trichoderma longibrachiatum. Main types of IFD included intravascular Candida infection (38.5%) and surgical‐site and intra‐abdominal candidiasis (23.1% each). Reported reasons for initiating rezafungin were the presence of fluconazole‐resistant isolates (53.8%), facilitating outpatient antifungal therapy (30.8%) and avoiding anticipated drug–drug interactions with triazoles (15.4%). No patient received rezafungin as a first‐line treatment and most (92.3%) had been previously exposed to other echinocandins. Rezafungin was typically initiated upon clearance of follow‐up blood cultures (80.0%). Median number of weekly doses was 4.0 (interquartile range: 3.0–5.5). Clinical cure (complete or partial response) by day +30 was achieved in all evaluable patients (100.0% [12/12]), with no treatment‐emergent adverse events.
Conclusions
Rezafungin was effective and safe as salvage or consolidation therapy in patients with IFD, including deep‐seated candidiasis.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Unit of Infectious Diseases, Hospital Universitario 12 de Octubre, Instituto de Investigación Hospital 12 de Octubre (imas12), Madrid, Spain.
- Centro de Investigación Biomédica en Red de Enfermedades Infecciosas (CIBERINFEC), Instituto de Salud Carlos III (ISCIII), Madrid, Spain.
- School of Medicine, Universidad Complutense, Madrid, Spain.
- Department of Microbiology, Hospital Universitario 12 de Octubre, Instituto de Investigación Sanitaria Hospital 12 de Octubre (imas12), Madrid, Spain.
- Department of Pharmacy, Hospital Universitario 12 de Octubre, Instituto de Investigación Sanitaria Hospital 12 de Octubre (imas12), Madrid, Spain.
ORCID-Profile: Jorge Boán, Eduardo Aparicio-Minguijón, Mario Fernández-Ruiz, María Asunción Pérez-Jacoiste Asín, Isabel Rodríguez-Goncer, Francisco López-Medrano, Rafael San-Juan, José Tiago Silva, Ana Pérez-Ayala, Jose Manuel Caro-Teller, José María Aguado
Förderung
- Instituto de Salud Carlos III (ISCIII), Spanish Ministry of Science, Innovation and Universities.
- Instituto de Salud Carlos III
Zitieren
APA
Boán, J., Aparicio-Minguijón, E., Fernández-Ruiz, M., Pérez-Jacoiste Asín, M. A., Rodríguez-Goncer, I., López-Medrano, F., San-Juan, R., Silva, J. T., Pérez-Ayala, A., Caro-Teller, J. M., & Aguado, J. M. (2026). Rezafungin for Salvage or Consolidation Therapy of Invasive Fungal Disease: Experience in Real‐World Clinical Practice. Mycoses, 69(2). https://doi.org/10.1111/myc.70163
Vancouver
Boán J, Aparicio-Minguijón E, Fernández-Ruiz M, Pérez-Jacoiste Asín MA, Rodríguez-Goncer I, López-Medrano F, et al. Rezafungin for Salvage or Consolidation Therapy of Invasive Fungal Disease: Experience in Real‐World Clinical Practice. Mycoses. 2026;69(2). doi:10.1111/myc.70163
BibTeX
@article{Bon2026,
author = {Boán, Jorge and Aparicio-Minguijón, Eduardo and Fernández-Ruiz, Mario and Pérez-Jacoiste Asín, María Asunción and Rodríguez-Goncer, Isabel and López-Medrano, Francisco and San-Juan, Rafael and Silva, José Tiago and Pérez-Ayala, Ana and Caro-Teller, Jose Manuel and Aguado, José María},
title = {Rezafungin for Salvage or Consolidation Therapy of Invasive Fungal Disease: Experience in Real‐World Clinical Practice},
journal = {Mycoses},
year = {2026},
volume = {69},
number = {2},
doi = {10.1111/myc.70163}
}
EUVIMED